

## Drug and Therapeutics Committee – Minutes – approved

<b>Date / Time</b>	9 <sup>th</sup> April 2015
<b>Venue</b>	The Board Room, Alderson House, HRI
<b>Chair</b>	Prof A Morice, Chair, Professor of Respiratory Medicine
<b>Notes / Action Points</b>	Mrs Wendy Hornsby, Senior Pharmacy Technician.
<b>Quorate: Yes / No</b>	Yes

<b>Attendance</b>	Mr S Gaines, Professional Secretary, Senior Principal Pharmacist – Clinical Services Mr P O'Brien, Deputy Chief Pharmacist Prof M Lind, Vice Chair, Professor of Oncology Mrs F Umerah, Consultant Anaesthetist Dr L Witvliet, GP Prescribing Lead, Hull CCG Dr O Ogunbambi, Consultant Rheumatologist Mr K McCorry, Local Pharmaceutical Advisor, ER CSU
-------------------	---

<b>Apologies</b>	Mr D Corral, Chief Pharmacist, Clinical Director Therapy & Therapeutics Dr H Klonin, Consultant Paediatrician Dr E Williamson, Consultant Microbiologist Mrs K Beal, Lay Trust Member
------------------	--

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
2015.04.01	<b>Apologies</b>	As above.					
2015.04.02	<b>Declarations of Interest</b>	There were no declarations of interest.	Noted.	No further action			4/15
2015.04.03	<b>Minutes of the previous meeting</b>	The minutes were accepted as a true record. Previous minutes section 2015.03.10 stated that octreotide was used in the treatment of chronic cough this needs to be altered to bronchorrhea.	Previous minutes and tracker to be amended.	WH to amend	WH	5/15	
2015.04.04	<b>Action Tracker</b>	<p>HERPC Minutes JLy not present to discuss Ezetimibe prescribing information.</p> <p>HERPC Minutes AM to write to cardiology once Ezetimibe prescribing information available.</p> <p>HERPC Minutes New Action: It was agreed that AM would write to HERPC on behalf of D&amp;T and recommend that Ezetimibe should not be initiated in primary care unless on the recommendation of a cardiologist.</p> <p>New Product Requests Eculizumab with HST1 link has been added to formulary</p>	<p>Could not discuss</p> <p>Awaiting prescribing information</p> <p>Primary care to be asked not to initiate Ezetimibe</p> <p>Action complete</p>	<p>Discuss next time</p> <p>Discuss next time</p> <p>AM to write to HERPC</p> <p>No further action</p>	<p>JLy</p> <p>AM</p> <p>AM</p> <p>WH</p>	<p>3/15</p> <p>4/15</p> <p>5/15</p> <p>4/15</p>	

		<p>New Product Requests POB has drafted an IFR request flow chart which will be discussed at next month's meeting</p>	Action complete	To be discussed at next meeting	POB		4/15
		<p>New Product Requests AM has written to the diabetes team to request confirmation of 1<sup>st</sup>, 2<sup>nd</sup> and 3<sup>rd</sup> line treatment.</p>	Action complete	No further action	AM		4/15
		<p>NICE guidance Sofosbuvir, formulary has been updated with "as per NICE guidance and commissioning position"</p>	Action complete	No further action	WH		4/15
		<p>NICE guidance Golimumab formulary has been updated to include "for use in gastro"</p>	Action complete	No further action	WH		4/15
		<p>NICE guidance Axitinib – SG has written to SS to request a submission</p>	Action complete	No further action	SG		4/15
		<p>NICE guidance Simeprevir formulary has been updated to include "as per NICE guidance"</p>	Action complete	No further action	WH		4/15
		<p>Review of Diclofenac tablet use at HEY SG has reviewed and the committee has agreed to remove from all areas with the exception of ward 15 CHH and maternity wards.</p>	New Action:SG to arrange for removal from ward stock		SG	5/15	
		<p>Drug Policy – Oral Chemotherapy DC was unavailable but ML attended the consultants meeting and informed the committee that the wording had been redrafted and that a flow chart had also been produced and would be discussed next time.</p>	Action complete	No further action	DC		4/15

		<p>Correspondence Received SG has spoken to AC regarding producing a leaflet for the unlicensed use of octreotide in bronchorrea.</p> <p>Any Other Business SG has notified the pain team of NHSE guidance on pregabalin.</p> <p>Any Other Business SG has discussed Humalog 200iu/ml with Dr Allen who has agreed to discuss and next consultant meeting.</p>	<p>Action Complete</p> <p>Action Complete</p> <p>Action complete</p>	<p>No further action</p> <p>No further action</p> <p>No further action</p>	<p>SG</p> <p>SG</p> <p>SG</p>		<p>4/15</p> <p>4/15</p> <p>4/15</p>
2015.04.05	<b>New Product Requests</b>	There were no new product requests to discuss this month.	Noted	No further action			4/15
2015.04.06	<b>NICE Guidance</b>	<ul style="list-style-type: none"> <li>CG28 Depression in Children &amp; Young People</li> <li>TA337 Rifaximin for preventing episodes of overt hepatic encephalopathy</li> <li>TA336 Empagliflozin in combination therapy for treating type 2 diabetes</li> <li>TA338 Pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib</li> </ul>	<p>All drugs on formulary</p> <p>Already on formulary and red list</p> <p>Position in treatment flowchart to be specified</p> <p>Pomalidomide is currently on CDF but not on formulary</p>	<p>No further action</p> <p>No further action</p> <p>SG to write to diabetes team</p> <p>No further action</p>	<p>SG</p>	<p>5/15</p>	<p>4/15</p> <p>4/15</p> <p>4/15</p>

		<ul style="list-style-type: none"> <li>TA335 Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome – meeting being arranged between primary and secondary care to discuss</li> </ul>	On formulary, no issues for D&T	No further action			4/15
2015.04.07	<b>MHRA Drug Safety update</b>	<p><b>March 2015</b> Dimethyl Fumarate – 1 case of fatal PML in an MS patient reported.</p> <p>Ferumoxytol (Rienso) – no longer available for use</p>	<p>Noted</p> <p>Remove from formulary</p>	<p>No further action</p> <p>WH to remove from formulary</p>			
2015.04.08	<b>Minutes from Hull and East Riding Prescribing Committee</b>	<p>January 2015 WH to ensure “via IFR only” has been added to entries for Eflornithine and Oral Ketamine.</p>	WH to update formulary		WH	5/15	
2015.04.09	<b>Correspondence Received</b>	<p>Ferumoxytol (Rienso) withdrawn from market</p> <p>Unlicensed Fosfomycin – there is now a licensed preparation available, however this preparation does not have an indication for use in CF.</p>	<p>See DSU</p> <p>Remove from unlicensed list and add to formulary</p>	<p>WH to update formulary</p>	WH	5/15	
2015.04.10	<b>Chairs Approvals</b>	Vedolizumab – Colitis Dr S Sebastian	Noted	No further action			4/15
2015.04.11	<b>D&amp;T Attendance 2014/15</b>	The committee were presented with a report highlighting attendance over the past 12 months. It was agreed that there was a need for a surgical clinician to attend more frequently.	SG to raise at surgery governance meeting and FU to discuss with anaesthetists.		SG/FU	5/15	

2015.04.12	<b>New Product Requests 2014/15</b>	The committee has processed 27 new product requests in the previous 12 months, with 25 approvals and 1 rejection and 1 deferred.	Noted	No further action			5/15
2015.04.13	<b>Issues to escalate to Operational Quality Committee</b>	None.	No further action.				5/15
2015.04.14	<b>Any other Business</b>	ML felt that the opiate conversion chart currently used in QCOH could be useful in other areas of the trust eg AAU. As the current acute pain guideline is being updated there is an opportunity to include this chart.  FU informed the committee that she had discussed HES with the anaesthetic dept due to the products re licensing and the dept had agreed not to re introduce the product at this time.	ML/SG to request acute pain team discuss use of chart.  Noted		ML/SG	5/15	
2015.04.15	<b>Date and Time of Next Meeting</b>	Thursday 14 <sup>th</sup> May 2015, 8.15am – 9.30am. The Committee Room, Alderson House, HRI					